Imageens Announces MDR CE-Certification for ArtFun+

Artfun+, powered by Imageens, has received Class 2a approval under the EU’s new Medical Device Regulation (EU MDR), becoming the Europe’s first MDR CE class 2a medical device for predictive cardiovascular medicine.

Artfun+ is the world’s most clinically validated device measuring MRI imaging biomarkers related to arterial stiffness and cardiovascular diseases. This breakthrough promises to transform cardiovascular risk assessment for clinicians worldwide.

Cardiovascular diseases are a global cause of mortality, emphasizing the need for accurate and timely diagnosis. Traditional risk assessment methods are labor-intensive and prone to errors. ArtFun+ harnesses AI and medical imaging for precise risk assessments.

Artfun+ is an AI-powered tool analyzing MRI scans to identify specific biomarkers linked to cardiovascular diseases. By accurately measuring these markers, Artfun+ equips healthcare professionals with vital information for tailored treatment plans.

The Class 2a approval demands rigorous validation, making Artfun+ a reliable and clinically validated tool for the medical community. This certification sets a new benchmark for AI-driven healthcare solutions, paving the way for future innovations in medical imaging.

Anas Dogui, Ph.D., Founder of Imageens, expresses excitement about this achievement, validating Artfun+’s exceptional performance and clinical relevance. The mission is to provide accurate tools for data-driven decisions and improved patient outcomes.

“By enabling accurate measurement of MRI imaging biomarkers, Artfun+ promises to revolutionize cardiovascular care and significantly impact patient outcomes. This achievement highlights AI-driven medical imaging solutions’ potential in improving healthcare and saving lives.”